Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 662-677

  Hiranita, Takato ^a   Soto, Paul L ^a   Kohut, Stephen J ^a   Kopajtic, Theresa ^a   Cao, Jianjing ^a   Newman, Amy H ^a   Tanda, Gianluigi ^a   Katz, Jonathan L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 9 [3 [CIS 3,5 DIMETHYL 4 (3 PHENYLPROPYL) 1 PIPERAZINYL]PROPYL]CARBAZOLE HYDROBROMIDE; [3 [CIS 3,5 DIMETHYL 4 (3 PHENYLPROPYL) 1 PIPERAZINYL]PROPYL]DIPHENYLAMINE HYDROCHLORIDE; AC 927; BD 1063; COCAINE; DOPAMINE TRANSPORTER; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 4 METHYLPIPERAZINE DIHYDROCHLORIDE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; N PHENETHYLPIPERIDINE OXALATE; N,N DIPROPYL 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL]ETHYLAMINE MONOHYDROCHLORIDE; NOMIFENSINE; OPIATE ANTAGONIST; RIMCAZOLE; SH 3 24; SH 3 28; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; REINFORCEMENT;

ANIMALS; ANISOLES; ANTIPSYCHOTIC AGENTS; CARBAZOLES; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; MOLECULAR TARGETED THERAPY; OXALIC ACIDS; PIPERIDINES; PROPYLAMINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 80054792966     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185025     Document Type: Article

References (41)

1. Adkins EM, Samuvel DJ, Fog JU, Eriksen J, Jayanthi LD, Vaegter CB, Ramamoorthy S, and Gether U (2007) Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 46:10484-10497. (Pubitemid 47417244)
2. Barrett AC, Miller JR, Dohrmann JM, and Caine SB (2004) Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47 (Suppl 1):256-273. (Pubitemid 39298269)
3. Borison RL, Diamond BI, and Dren AT (1991) Does ≲δλ τα∀ receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 27:103-106.
4. Cao J, Kulkarni SS, Husbands SM, Bowen WD, Williams W, Kopajtic T, Katz JL, George C, and Newman AH (2003) Dual probes for the dopamine transporter and δ1 receptors: novel piperazinyl alkyl-bis(4′-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J Med Chem 46:2589-2598. (Pubitemid 36702528)
5. Connor MA and Chavkin C (1992) Ionic zinc may function as an endogenous ligand for the haloperidol-sensitive δ2 receptor in rat brain. Mol Pharmacol 42:471-479.
6. de Costa BR, He XS, Linders JT, Dominguez C, Gu ZQ, Williams W, and Bowen WD (1993) Synthesis and evaluation of conformationally restricted N-[2-(3,4- dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at δ receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds. J Med Chem 36:2311-2320.
7. de Costa BR, Radesca L, Di Paolo L, and Bowen WD (1992) Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1- pyrrolidinyl)ethylamines: structural requirements and binding affinity at the δreceptor. J Med Chem 35:38-47.
8. Ferrer JV and Javitch JA (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci USA 95:9238-9243. (Pubitemid 28506215)
9. Foster JD, Adkins SD, Lever JR, and Vaughan RA (2008) Phorbol ester induced traffickingindependent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 105:1683-1699. (Pubitemid 351678491)
10. Frederickson CJ, Koh JY, and Bush AI (2005) The neurobiology of zinc in health and disease. Nat Rev Neurosci 6:449-462. (Pubitemid 40774861)
11. Fu Y, Zhao Y, Luan W, Dong LY, Dong Y, Lai B, Zhu Y, and Zheng P (2010) Sigma-1 receptors amplify dopamine D1 receptor signaling at presynaptic sites in the prelimbic cortex. Biochim Biophys Acta 1803:1396-1408.
12. Garcés-Ramírez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas AM, Mesangeau C, Narayanan S, McCurdy CR, Katz JL, et al. (2011) Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis in rats. Biol Psychiatry 69:208-217.
13. Gebreselassie D and Bowen WD (2004) Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol 493:19-28. (Pubitemid 38746928)
14. Gonzalez-Alvear GM and Werling LL (1994) Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 271:212-219.
15. 2+ concentration. J Pharmacol Exp Ther 293:788-798.
16. 1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther 306:718-725.
17. Hayashi T and Su TP (2005) The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci 77:1612-1624. (Pubitemid 41073656)
18. Hiranita T, Soto PL, Newman AH, and Katz JL (2009) Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329:677-686.
19. Hiranita T, Soto PL, Tanda G, and Katz JL (2010) Reinforcing effects of δ-receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther 332:515-524.
20. Hong WC and Amara SG (2010) Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem 285:32616-32626.
21. Husbands SM, Izenwasser S, Kopajtic T, Bowen WD, Vilner BJ, Katz JL, and Newman AH (1999) Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3,5-dimethyl-1-piperazinyl) propyl]carbazole (rimcazole) analogues. J Med Chem 42:4446-4455. (Pubitemid 29504148)
22. Izenwasser S, Newman AH, and Katz JL (1993) Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur J Pharmacol 243: 201-205. (Pubitemid 23308523)
23. Katz JL, Libby TA, Kopajtic T, Husbands SM, and Newman AH (2003) Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol 468:109-119. (Pubitemid 36556254)
24. Katz JL, Su TP, Hiranita T, Hayashi T, Tanda G, Kopajtic T, and Tsai SY (2011) A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals 4:880-914.
25. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823. (Pubitemid 351397886)
26. 2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci USA 99:1683-1688.
27. Martin-Fardon R, Maurice T, Aujla H, Bowen WD, and Weiss F (2007) Differential effects of sigma1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacology 32:1967-1973. (Pubitemid 47258516)
28. Matsumoto RR (2009) Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev Clin Pharmacol 2:351-358.
29. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, and Bowen WD (2001) Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 419:163-174. (Pubitemid 32568215)
30. Maurice T and Su TP (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206.
31. Menkel M, Terry P, Pontecorvo M, Katz JL, and Witkin JM (1991) Selective δ ligands block stimulant effects of cocaine. Eur J Pharmacol 201:251-252.
32. Mésangeau C, Narayanan S, Green AM, Shaikh J, Kaushal N, Viard E, Xu YT, Fishback JA, Poupaert JH, Matsumoto RR, et al. (2008) Conversion of a highly selective sigma-1 receptor-ligand to sigma-2 receptor preferring ligands with anticocaine activity. J Med Chem 51:1482-1486. (Pubitemid 351480410)
33. Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortés A, Casadó V, Canela EI, Ortiz J, et al. (2010) Direct involvement of δ-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci USA 107:18676-18681.
34. Reith ME, Berfield JL, Wang LC, Ferrer JV, and Javitch JA (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018.
35. Romieu P, Meunier J, Garcia D, Zozime N, Martin-Fardon R, Bowen WD, and Maurice T (2004) The sigma 1 (δ1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology (Berl) 175:154-162. (Pubitemid 39222345)
36. Romieu P, Phan VL, Martin-Fardon R, and Maurice T (2002) Involvement of the sigma1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26:444-455. (Pubitemid 34260994)
37. Su TP and Hayashi T (2001) Cocaine affects the dynamics of cytoskeletal proteins via sigma1 receptors. Trends Pharmacol Sci 22:456-458.
38. Tam SW (1983) Naloxone-inaccessible a receptor in rat central nervous system. Proc Natl Acad Sci USA 80:6703-6707.
39. Ujike H, Kanzaki A, Okumura K, Akiyama K, and Otsuki S (1992) Sigma (δ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 50:PL129-PL134.
40. Wachtel SR and White FJ (1988) Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. J Pharmacol Exp Ther 244:410-416. (Pubitemid 18042411)
41. Witkin JM, Terry P, Menkel M, Hickey P, Pontecorvo M, Ferkany J, and Katz JL (1993) Effects of the selective sigma receptor ligand, 6-[6-(4- hydroxypiperidinyl-) hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther 266:473-482. (Pubitemid 23318650)